David McNeely, MD
Cardiovascular Disease · Greenville, SCNPI 1285952705
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,939 of the $77,692 with a category attached, or 63.0%. AstraZeneca accounts for 65.8% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2020 at $21,161 and has fallen 89.0% since, to $2,330 in 2025. Among cardiovascular disease clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 465 payments — averaging $167.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$51K
- Edwards Lifesciences$10K
- Abbott$8K
- Boston Scientific$2K
- Novartis$1K
- Heartflow, Inc.$650
- plus $4K from 31 others
What the payments were for
- Consulting fees$7,95010%
- Speaking & faculty fees$48,93963%
- Travel & lodging$6,7339%
- Food & beverage$13,80418%
- Education$2660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 83 | $51,088 |
| Edwards Lifesciences | 11 | $10,142 |
| Abbott | 74 | $8,438 |
| Boston Scientific | 66 | $2,192 |
| Novartis | 61 | $1,080 |
| Heartflow, Inc. | 7 | $650 |
| Amgen | 21 | $474 |
| Boehringer Ingelheim | 27 | $466 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $446 |
| Alnylam Pharmaceuticals Inc. | 18 | $300 |
| Siemens Medical Solutions USA, Inc. | 3 | $236 |
| Astellas Pharma US Inc | 5 | $178 |
| Johnson & Johnson | 9 | $175 |
| Impulse Dynamics (USA) Inc. | 1 | $173 |
| E.r. Squibb & Sons, L.L.C. | 11 | $166 |
| Pfizer | 5 | $162 |
| Abiomed | 3 | $150 |
| Trisalus Life Sciences, Inc. | 1 | $140 |
| Bayer | 7 | $131 |
| Philips North America LLC | 6 | $130 |
| Actelion Pharmaceuticals US, Inc. | 1 | $123 |
| Merck | 7 | $111 |
| Atricure, Inc. | 5 | $103 |
| Teleflex LLC | 2 | $80 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $56 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $46 |
| Novo Nordisk | 2 | $43 |
| Terumo Medical Corporation | 1 | $32 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Daxor Corporation | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $24 |
| Cardiovascular Systems Inc. | 2 | $23 |
| Cvrx, Inc. | 1 | $21 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Convatec Inc. | 1 | $14 |
| Medtronic | 1 | $13 |
| Chiesi USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$49,512
- Edwards SAPIEN 3 Transcatheter Heart Valve$7,950
- Mitra Clip system$2,755
- MitraClip$2,242
- WATCHMAN FLX$685
- FFRct$468
- OPTIMIZER$346
- AMPLATZER$280
- LifeVest$246
- Watchman$231
- EVOQUE$203
- CARDIOMEMS$202
- TRINAV INFUSION SYSTEM$140
- TRICLIP$133
- UPTRAVI$123
- OPSUMIT$123
- MAGNETOM Sola$120
- Farapulse$119
- VYNDAQEL$110
- MitraClip System$109
How this compares
$77,692 in reported general payments places this provider in the 95th percentile of 257 cardiovascular disease providers in South Carolina.
See all cardiovascular disease providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 304 | $338,044 |
| EntrestoSacubitril/Valsartan | 77 | $97,970 |
| Repatha SureclickEvolocumab | 82 | $97,837 |
| JardianceEmpagliflozin | 48 | $56,771 |
| FarxigaDapagliflozin Propanediol | 51 | $55,614 |
| XareltoRivaroxaban | 55 | $52,232 |
| Metoprolol Succinate | 347 | $5,135 |
| Rosuvastatin Calcium | 241 | $4,123 |
| Flecainide Acetate | 44 | $2,917 |
| Atorvastatin Calcium | 232 | $2,502 |
| Ezetimibe | 24 | $1,673 |
| Losartan Potassium | 174 | $1,312 |
| Amlodipine Besylate | 177 | $1,215 |
| Pravastatin Sodium | 55 | $967 |
| Nitroglycerin | 118 | $961 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $162 | $338,044304 claims |
| NovartisEntresto | $1,080 | $97,97077 claims |
| Boehringer IngelheimJardiance | $466 | $56,77148 claims |
| AstraZenecaFarxiga | $51,088 | $55,61451 claims |
| Johnson & JohnsonXarelto | $175 | $52,23255 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 257 cardiovascular disease providers in South Carolina.
Other cardiovascular disease in Greenville
- Gregory SanGreenville$88K
- Christopher SalmonGreenville$54K
- Arthur EberlyGreenville$34K
- Tara HolderGreenville$20K
- Dev VazGreenville$14K
- Jon BittrickGreenville$13K
- James MerriamGreenville$11K
- Harold BlanksGreenville$9K
- Arthur SiachosGreenville$9K
- Robert BiedermanCharleston$775K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.